EGFR and neoplasm: The changes observed in RTK protein levels in tumors of mice treated with cetuximab or with INC280 and trametinib were consistent with those observed for 89Zr-labeled antibody tumor uptake and collectively suggest a mechanism of resistance of this EGFR-expressing PDX to cetuximab (Fig. 3; Supplemental Fig. 5).